INTRODUCTION
Breast cancer was the most common cancer in women and one of the most important health issues in women that should receive serious attention. In developed countries, breast cancer incidence rate continue to rise and is the number two cause of death from cancer after lung cancer.
11.5% of all breast cancer patients. The incidence of early age onset breast cancer in the USA was 1.3/100,000 in the age group 20-24 years and up to 61.7/100,000 in the age group 35-39 years.
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The management of early age onset stage III breast cancer or Locally Advanced Breast Cancer (LABC) is the same as stage III breast cancer in general. Stage III breast cancer is a heterogeneous group of breast cancer generally consists of large primary tumors (more than 5 cm) with or without infiltration into the skin or chest wall (T3 / T4), or breast cancer patients with lymph node metastases in the axillary lymph nodes, internal mammary lymph nodes or ipsilateral supraclavicular lymph nodes (N2 / N3).
6
Stage III breast cancer provides a unique challenge for physicians who manage breast cancer patients. Stage III breast cancer treatment requires a multidisciplinary approach ranging from diagnosis is made until further therapy. Patients with stage III breast cancer have a higher risk to be a systemic disease and the risk of micrometastasis remains high despite absence of systemic metastasis.
7
There has been a paradigm shift during the 1970s which states that breast cancer is a systemic disease, where its survival rate is dependent on eradicating the presence of micrometastasis, ever since the development of multimodality therapy has been accepted for stage III breast cancer.
Multimodality therapy, which consists of local-regional and systemic chemotherapy (neoadjuvant and adjuvant), is now an option in the treatment of patients with stage III breast cancer.
7,8
Clinical trials of neoadjuvant combination chemotherapy (also called induction chemotherapy or preoperative chemotherapy or primary chemotherapy) were first introduced by Skipper and Schabel in 1960, and the first report was published in 1970. The summary of some recent research report states that the combination of neoadjuvant chemotherapy in stage III breast cancer showed Partial Response (PR) 50-98%, and the Complete Clinical Response (cCR) 5-52%, as well as Pathologic Complete Response (pCR) 4-28%.
7, 9 Research from Sanglah General Hospital showed that 83.3% of patients responded positively, whereas in 16.7% of patients showed negative response.
10 Subsequent studies showed a decrease in the response to chemotherapy, 39.4% positive response and 60.6% negative response, this was probably attributed to the larger diameter of the tumor and clinical tumor volume measurement difficulties, 11 while Susilo (2008) found 41.3% positive response and 58.8% negative response.
12
The main advantage of neoadjuvant combination chemotherapy is the effect of downsizing period of the primary tumor or metastases in axillary lymph nodes (downstaging), eradication of micrometastasis presence without delay, to evaluate the response to chemotherapy given in vivo, and if the downstaging effect is achieved, breast conserving surgery (BCS) can be taken into consideration.
13
Many factors influence the presence or absence of breast cancer response to neoadjuvant chemotherapy combinations, e.g.: patient age (younger patient is more resistant than the older); and the volume of the tumor (bigger tumor is more resistant).
7, 14 Higher histological grade was associated with better response to chemotherapy; certain histopathologic type (tubular carcinoma, medullary); and the presence or absence of steroid receptors (ER, PR).
14 Several molecular markers such as the expression of ERBB2/HER2/neu, proliferation factors expression such as MiB1, Ki67, angiogenesis factor VEGF/VEGFR, as well as the amount of apoptosis (apoptotic index), affect the response of neoadjuvant combination chemotherapy.
11,13
Research in the field of molecular biology to determine the expression of several biomarkers for neoadjuvant combination chemotherapy response has been underway. Biological markers were expected to be predictive for chemotherapy response. 15 This is important because patients who do not respond to neoadjuvant combination chemotherapy, will experience delay in the selection of treatment modality which will result in inadequate treatment, commonly referred to as loss of window of opportunity.
2,7,16
Various studies have shown differences in clinical, pathological, and biological characteristics of early age onset breast cancer. Early age onset breast cancer generally has poor clinical characteristics such as more advanced stage and more aggressive growth. Pathologically: more aggressive, higher histological grading, positive lymphatic vascular invasion (LVI). Biologically more aggressive characteristics such as negative ER, DNA aneuploidy, high proliferation rate: Ki-67 or MIB1 expressed, ERBB2/HER2/neu positive, positive P53, BRCA1/2 gene mutation, and so forth. Thus it will have a poor prognosis as well.
4,17
Early age onset breast cancer is generally more aggressive, high proliferation rate with Ki-67 or MIB1 overexpression. High proliferation rate causes hypoxia in the central part of the tumor tissue because of vascularization and nutritional disorders, and increased intratumoral interstitial pressure. This state will stimulate angiogenesis process which is characterized by increased expression of vascular endothelial growth factor / receptor (VEGF/VEGFR), and in turn causes decreased response to chemotherapy.
14,18
Ki-67 protein overexpression was highly correlated with higher mitotic activity, higher histological grading, and larger tumor S-phase fraction. Clinically, Ki-67 protein expression was correlated with high primary tumor size, presence of axillary lymph node ORIGINAL ARTICLE metastasis, mutant p53 expression, positive ERBB2/ HER-2/neu, negative ER/PR, higher chemotherapy resistance and poorer prognosis.
14,19
Vascular endothelial growth factor/receptor (VEGF/VEGFR) is a major angiogenic factor in cancer cells, due to its angiogenic and lymphangiogenic properties which can promote the growth and metastasis of cancer. Currently there has been six types of VEGF identified: VEGF-A, placental growth factor (PIGF-1 and PIGF-2), VEGF-B, VEGF-C, VEGF-D, and VEGF-E. VEGF is expressed by tumor cells, macrophages, T cells, smooth muscle cells, kidney cells, keratinocytes, astrocytes and osteoblasts.
20
Several angiogenic factors are often overexpressed in breast cancer. Increased expression of VEGF in patients with breast cancer is usually associated with a poor prognosis. High VEGF expression is often found in patients with more aggressive breast cancer, with negative ER/PR, positive p53 expression, positive ERBB2/HER2/neu, or in patients with TripleNegative Breast Cancer. These properties are often found in early age onset breast cancer. Abnormal angiogenesis in tumors was suspected to affect chemotherapy response. Increased VEGF expression is associated with immunosuppression and poor response to tamoxifen or chemotherapy administration in patients with advanced breast cancer.
21-23
Based on the description above, several research problems were formulated: 
MATERIAL AND METHOD
This was a hybrid design research using cross-sectional and nested case-control design. The independent variables in this study were Ki-67 and VEGF protein expression; the dependent variables were chemotherapy response. Confounding variables were primary tumor size, histopathological grade, estrogen receptor expression, progesterone receptor expression, Her-2/ neu expression, and p53 protein expression. Data was analyzed descriptively to determine research samples characteristics and an inferential analysis was performed using Chi-square test (p<0.05 was considered significant) to determine the association between dependent variables Ki-67 and VEGF expression with neoadjuvant combined chemotherapy response. In the case-control study, data was analyzed with Chi-square test and Odds Ratio was determined (95% Confidence Interval, p<0.05 was considered significant). Confounding variables (primary tumor size, histological grade, ER, PR, Her-2/Neu, p53) were analyzed with unconditional logistic regression analysis.
RESULTS

From 1 September 2012 until 31 March 2014
there has been 80 patients with stage III early age onset breast cancer who received CAF neoadjuvant combination chemotherapy from Sanglah General Hospital and Prima Medika Hospital Denpasar. From the 66 samples that met the inclusion criteria, the mean age was 34.53±3.548; the youngest age was 27 years old. The mean value of the tumor diameter was 9.317±4.207 centimeters. Most tumors (63.6%) were high grade and 30.8% were TNBC subtype (triple negative breast cancer). Positive response with neoadjuvant combination chemotherapy CAF was observed in only 47.0% samples, with a clinical complete response (CCR) of 6.1%, as shown in figure 3 . Cross-sectional study sample characteristics are shown in Table 1 .
Association between Ki-67 Protein Expression with Neoadjuvant Combined Chemotherapy in Stage III Early Age Onset Breast Cancer
The association between confounding variables (primary tumor size, histological grade, tumor stage, TIL, LVI, ER, PR, Her-2/Neu, and p53) and neoadjuvant combined chemotherapy response were analyzed as seen on Immunohistochemistry staining showed >14% strong intensity brownish coloration on the nucleus of breast cancer cells using 40X magnification Table 4 .
Result from VEGF Protein Immunohistochemistry (IHC) Staining
Case-Control Study Sample Characteristics
The samples for the case-control study were taken from the cross-sectional study, 31 samples as case (samples with negative chemotherapy response) and 31 samples as control (samples with positive Immunohistochemistry staining showed >10% strong intensity brownish coloration on the cytoplasm of breast cancer cells using 40X magnification chemotherapy response). Comparison between the case and control samples can be seen in Table 5 .
Risk Factors (Odds Ratio) in the Case-Control Study Variables
Bivariate analysis from the case-control study showed that several variables had an Odds Ratio greater than one; primary tumor (1.484), p53 expression (2.192), Ki-67 protein expression (4.747), and VEGF expression (2.879); but only Ki-67 and VEGF protein expression showed p value <0.05. Results from the case-control bivariate analysis are shown in Table 6 .
A multivariate analysis using logistic regression was performed following the bivariate analysis of the case-control study samples. Multivariate analysis showed Ki-67 protein expression had an Adjusted Odds Ratio of 4.747 (p=0.006; CI 95% 1.575-14.312).
DISCUSSION
Early age onset breast cancer or breast cancer which occur before 40 years of age showed different biological characteristics compared to breast cancer occurring later in life. In general, early age onset breast cancer was associated with more aggressive tumor, poorer prognosis, more resistant to conventional therapies, and was one of the major cause for cancer related death in young women. Early age onset breast cancer (<40 years old) was relatively uncommon, but an epidemiological study showed that there was a decrease in age onset for breast cancer in developing countries.
4
From September 1st 2012 to March 31st 2014, there were 80 patients with early age onset breast cancer (<40 years) who received neoadjuvant combined chemotherapy CAF in Sanglah General Hospital and Prima Medika Hospital Denpasar. From the 80 patients, 66 patients were eligible based on the inclusion criteria. The mean age was 34.53 ± 3.548 years old; the youngest patient was 27 years old.
The proportion of early age onset breast cancer in the United States was estimated 11.5% of all breast cancer. The incidence of early age breast cancer was 1.3/100000 (20-24 years) and 61.7/100000 (35-39 years) in the United States.
3,5
The incidence of Locally Advanced Breast Cancer (LABC) or stage III breast cancer is only 5% in developed countries. But in developing countries, the incidence rate goes as far as 40-60%.
7
Approximately, more than 70% of breast cancer patients who seek treatment in Bali are stage III breast cancer. Based on observation, there was a tendency for breast cancer patients in Bali to be younger compared to developed countries, one 
10-12
The mean tumor diameter in this study was 9.317±4.207 cm; with the smallest on was 2.0 cm and the largest was 20.0 cm, 43.9% of the tumors had >10 cm diameter with the majority (62.5%) tumor stage was stage IIIB. Early age onset breast cancer often came with larger, more extensive tumor with lymph node involvement, usually multifocal/ multicentral, even bilateral or hereditary in nature. The cause of delay in seeking treatment were probably attributed to lack of knowledge or high density breast which make ultrasound/mammography interpretation difficult.
4,24,25
Based on the histopathological findings, the majority of early age onset breast cancer in this study showed invasive carcinoma of no special type with high tumor grade (63.6%), positive lymphatic vascular (LVI) (30.3%) and tumor infiltrating lymphocyte (TIL) (30.3%).
14,26
Several studies have found different biological characteristics of early age onset breast cancer. More aggressive biological markers commonly associated were ER/PR (-), DNA aneuploidy, high proliferation rate (Ki-67 and MIB1 expression), ERBB2/HER2/neu overexpression, p53 positive, BRCA1/2 mutation, and so forth.
4,17
Early age onset breast cancer was also associated with specific, more aggressive, molecular subtype of breast cancer (triple negative breast cancer, Her-2 type breast cancer). One study found a higher prevalence of basal like breast cancer subtype and lower luminal A breast cancer subtype in early age onset breast cancer (Partridge, et al., 2014) . Keegan, et al., 2012 found that the breast cancer subtypes in 15-39 years old patients were luminal A 49%, luminal B 22.8%, Her-2/neu type 17.9%, and TNBC 10.3%. In this study, we found that the majority of subtype was triple negative breast cancer (TNBC) (30.8%), followed by luminal B (29.2%), Her-2/neu type (21.5%) and luminal A (18.5%).
27
Several studies found that apoptotic markers such as positive p53 and positive BCL-2 were more frequently encountered in early age onset breast cancer.
14 In this study we found positive p53 expression in 54.5% samples and negative p53 expression in 45.5% samples.
Early age onset breast cancer management is basically the same with stage III breast cancer. The management for this breast cancer group poses a unique challenge and requires multidisciplinary/ multimodality approach. Combined multimodality therapy comprised of loco-regional therapy and systemic chemotherapy (neoadjuvant and adjuvant) has been the mainstay of treatment for stage III breast cancer patients. 
7,8
Neoadjuvant Combined Chemotherapy Response in Stage III Early Age Onset Breast Cancer
Neoadjuvant combined chemotherapy response is important in the management of early age onset breast cancer patients. It has been proven as a predictive factor for survival in stage III breast cancer, where the occurrence of pathologic complete response (pCR) after neoadjuvant combined chemotherapy administration will improve the prognosis significantly.
28
From the 66 samples in this study, 31 (47%) samples showed a positive response, where 40.9% showed partial response and 6.1% showed pathological complete response. Thirty-five (53%) samples showed negative response, where 43.9% showed no response and 9.1% showed progressive disease.
The majority of studies on neoadjuvant combined chemotherapy in stage III breast cancer used anthracycline-based chemotherapy. A clinical complete response (cCR) rate of 10-20% can be achieved, while pathologic complete response (pCR) rate was only 8-15%. A higher positive response rate up to 80-95% could be achieved using taxane-based chemotherapy, but there was no significant increase in cCR and pCR rate compared to anthracycline-based chemotherapy. In ERBB2 positive stage III breast cancer, the addition of trastuzumab can increase the pCR up to 20-70%.
13,28
A previous study in Sanglah General Hospital found that 83.3% patients showed positive response, while 16.7% patients showed negative response (Sudarsa, 2000) . A follow-up study showed a decrease in chemotherapy response; 39.4% positive response and 60.6% negative response.
11 Susilo (2008) found 41.3% positive response and 58.8% negative response. These results indicate that neoadjuvant combined chemotherapy (CAF) response in early age onset breast cancer patients was lower compared to similar studies in developed countries.
12 It was probably due to larger tumor size and difficulties in determining tumor volume clinically, using anthracycline-based chemotherapy and not taxane-or platinum-based chemotherapy, no targeting therapy administration such as trastuzumab in Her-2/neu positive or bevacizumab in TNBC patients, or PARP inhibitors in BRCA1/2 positive mutations.
Several factors were suspected to contribute in neoadjuvant combined chemotherapy response in stage III early age onset breast cancer. Analysis on confounding variables (tumor size, tumor stage, tumor grade, TIL, LVI, ER, PR, HER-2/neu, and p53) association with neoadjuvant combined chemotherapy CAF response in stage III early age onset breast cancer showed no significant results (p>0.05).
Association between Ki-67 Protein Expression with Neoadjuvant Combined Chemotherapy in Stage III Early Age Onset Breast Cancer
Sustaining proliferative signaling was one of the hallmarks of cancer, including breast cancer. Cancer cell proliferation is triggered by several factors such as Ki-67 or MIB1 protein, and several cyclins. The rate of cancer cell proliferation can be determined using several cell proliferation markers such as: histological grade, Mitotic Activity Index (MAI), S-Phase Fraction(SPF) and DNA ploidy through flow cytometry, Thymidine Labeling Index (TLI), Thymidine Kinase (TK), protein Ki-67 or MIB1, Cyclin E, and Cyclin D.
14,19,31
Early age onset breast cancer is generally aggressive, with high rate of proliferation, marked by high proliferation markers value such as Ki-67.
From the 66 cross sectional samples, 62.1% samples showed a positive Ki-67 expression. Bivariate analysis between Ki-67 protein expression with neoadjuvant chemotherapy response in stage III early age onset breast cancer showed a significant association (p<0.05) with an Odds Ratio 5.538 (CI 95% 1.856-16.524). The result answered our first research hypothesis, high Ki-67 protein expression is associated with poor neoadjuvant combined chemotherapy CAF response in stage III early age onset breast cancer.
Several studies support our finding where high Ki-67 protein expression (>14%) in breast cancer was considered as a negative prognostic factor and associated with poor anthracycline based neoadjuvant combined chemotherapy. 
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onset breast cancer showed a significant association (p<0.05) with an Odds Ratio 3.455 (95% CI 1.251-9.539). The result confirmed our second research hypothesis, which was high VEGF expression is associated with poor neoadjuvant combined chemotherapy CAF response in stage III early age onset breast cancer.
High VEGF expression is commonly found in more aggressive breast cancer, with negative ER/ PR, positive p53, positive ERBB2.Her2/neu, or in TNBC. Those characteristics were often found in early age onset breast cancer.
23
From the bivariate analysis of case-control samples, several variables showed an Odds Ratio value greater than one, the variables were: tumor size (1.484), p53 expression (2.192), Ki-67 protein expression (4.747), and VEGF expression (2.879), but only Ki-67 and VEGF protein expression showed p value <0.05.
Ki-67 Protein Expression as a Risk Factor for Neoadjuvant Combined Chemotherapy in Stage III Early Age Onset Breast Cancer
Bivariate analysis from the case-control study found that Ki-67 protein expression was significantly higher in the case group compared to the control group (OR = 4.747 CI 95% 1.575-14.312; p=0.004). While multivariate analysis using logistic regression method found the adjusted OR was 4.747 (CI 95% 1.575-14.312; p=0,006). The result showed that patients with high Ki-67 protein expression will have 5 times higher risk of developing poor neoadjuvant chemotherapy compared to patients with low Ki-67 protein expression. The third research hypothesis is answered by this analysis.
During the past decade, there have been a number of studies on the role of proliferation markers as prognostic or predictive factor in breast cancer. The role of Ki-67 as a proliferation marker in early or advanced breast cancer has been widely studied due to the simplicity of the examination, but unfortunately the results from these studies were not consistent (Colozza, et al., 2005) .
Up until now, the role of Ki-67 was considered prognostic in nature, due to the fact that high proliferation was associated with poorer prognosis. In this study, we found that high Ki-67 protein expression was an independent prognostic factor for poor neoadjuvant combined chemotherapy response. It was also associated with several poor prognostic factors such as tumor size, lymph node involvement, histologic grade, and vascular invasion, also with good prognostic factor ER/PR status.
14,34,35
A meta-analysis study of 12,000 patients with positive Ki-67 expression showed a significant association with higher recurrence rate and lower survival rate in patients with positive or negative lymph node involvement.
36
Up until now, there have been no significant findings on the role of Ki-67 as a predictive factor for neoadjuvant chemotherapy. One study stated that high Ki-67 expression will represent a high tumor proliferation rate hence it will lead to positive chemotherapy response. 35 But, it was not consistent with the concept where high proliferation rate will lead to central tumor hypoxia which will lead to poor chemotherapy response.
31, 37 The latter study supports our finding where in stage III early age onset breast cancer patients with aggressive, high proliferating behavior, will have a higher risk of poor neoadjuvant combined chemotherapy CAF.
Vascular Endothelial Growth Factor (VEGF) Expression as a Risk Factor for Neoadjuvant Combined Chemotherapy in Stage III Early Age Onset Breast Cancer
Bivariate analysis from the case-control study found that VEGF expression was significantly higher in the case group compared to the control group (OR = 2.879 CI 95% 1.026-8.074; p=0.042). But, multivariate analysis using logistic regression method found the adjusted OR was 2.553 (CI 95% 0.860-7.582; p=0.091). The result showed that patients with high VEGF expression will have 2.5 times higher risk of developing poor neoadjuvant chemotherapy compared to patients with low VEGF expression. Even though it was not statistically significant, high VEGF expression might have a role as a risk factor for poor neoadjuvant combined chemotherapy response in early age onset breast cancer. As stated in the samples size determination for the case-control study design, the power used in this study was 80%. Therefore it is still possible to gain more significant results by increasing the power of this study to 90%.
The association between high VEGF expression with neoadjuvant combined chemotherapy has not been established in this study. But VEGF/VEGFR overexpression has been associated with poor chemotherapy response due to impaired chemotherapy delivery inside the tumor.
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The most crucial elements in VEGF gene regulation was oxygen tension or hypoxia and tissue acidosis. Changes in pO2 and pH in tumor tissue will cause varieties in VEGF A gene expression, leading to alternative splicing producing several VEGF A isoforms: VEGF121, VEGF165, VEGF189, VEGF206, less common VEGF A isoforms are VEGF145 and VEGF183 (Ferrara et al, 2003; Ferrara, 2004) . We suspect that the presence of VEGF A isoforms affects the results of VEGF IHC staining. Several other factors might also contribute to VEGF mRNA expression, such as epidermal growth factor (EGF), PDGF-β, TGFβ1, keratinocyte growth factor (KGF) and interleukin-1 beta (IL-1β), IL-1 α and IL-6.
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As stated before, high VEGF expression was associated with a more aggressive breast cancer, negative ER/PR, positive e p53 expression, positive ERBB2/HER2/neu, or TNBC. Those features were commonly found in early age onset breast cancer.
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Until now, the main focus of VEGF (specifically VEGF A) studies was its role as a prognosis factor and the outcome in anti-VEGF therapy, bevacizumab. High VEGF expression was associated with increased angiogenesis and lymphangiogenesis, immunosuppression, and low apoptosis index. High VEGF expression in breast cancer was associated with poorer prognosis.
22,38
Recent studies found that combined chemotherapy and anti-angiogenesis administration as an adjuvant or neoadjuvant therapy is more effective in breast cancer management.
39
Novel Findings
There were several novel findings in this study: High Ki-67 and VEGF expression were associated with poor neoadjuvant combined chemotherapy response in stage III early age breast cancer. High Ki-67 expression was an independent risk factor for poor neoadjuvant combined chemotherapy response in stage III early age breast cancer. High VEGF expression might be a risk factor for poor neoadjuvant combined chemotherapy response in stage III early age breast cancer.
